Abstract
Topoisomerase II is a key target for many anti-cancer drugs used to treat breast cancer. In human cells there are two closely related, but differentially expressed, topoisomerase II isoforms, designated topoisomerase II alpha and beta. Here, we report the production of a new polyclonal antibody raised against a fragment of the C-terminal domain of the 180 kDa form of topoisomerase II (the beta isoform), which does not cross-react with the 170 kDa form (the alpha isoform). Using this antibody, together with a polyclonal antibody specific for the 170 kDa isoform of topoisomerase II, we have examined the relationship between the sensitivity of a panel of human breast cancer cell lines to different classes of topoisomerase II inhibitors and cellular levels of the topoisomerase II alpha and beta proteins. We found that sensitivity to amsacrine showed a correlation with the level of expression of topoisomerase II alpha protein, and that sensitivity to etoposide showed a similar correlation with the level of expression of topoisomerase II beta protein. There was also a relationship between sensitivity of these cell lines to mitoxantrone and the cellular level of both isoforms of topoisomerase II. No relationship was found between the level of mRNA for topoisomerase II alpha or beta, and either sensitivity of breast cancer cell lines to topoisomerase II inhibitors or the level of topoisomerase II protein expression.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Houlbrook, S., Addison, C., Davies, S. et al. Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines. Br J Cancer 72, 1454–1461 (1995). https://doi.org/10.1038/bjc.1995.529
Issue Date:
DOI: https://doi.org/10.1038/bjc.1995.529
This article is cited by
-
Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase IIα inhibitors
JBIC Journal of Biological Inorganic Chemistry (2020)
-
Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms
BMC Cancer (2019)
-
Comparative analysis of xanafide cytotoxicity in breast cancer cell lines
British Journal of Cancer (2007)
-
Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome
Leukemia (2004)
-
Topoisomerase II-α Expression in Different Cell Cycle Phases in Fresh Human Breast Carcinomas
Modern Pathology (2002)